'ADVANCE' (A Pilot Trial)
NCT03858322 is a phase 1 interventional trial sponsored by Dana-Farber Cancer Institute. As of 18 Nov 2026, it is active and no longer recruiting. It studies Carboplatin, Cyclophosphamide and Paclitaxel in Breast Cancer. The registry lists an enrollment of 41 participants at 5 sites in 1 country. The registry lists a start date of 21 Mar 2019 and a primary completion date of 10 Nov 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03858322 |
| Status | Active not recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Dana-Farber Cancer Institute |
| Enrollment | 41 |
| Registered sites | 5 |
| Countries | 1 |
| Conditions | Breast Cancer |
| Drugs | Carboplatin, Cyclophosphamide and Paclitaxel |
| Start | 21 Mar 2019 |
| Primary completion | 10 Nov 2020 |
| Study completion | 30 Dec 2026 |
| Last update posted | 13 Aug 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Rachel Freedman, MD, MPH
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope National Medical Center
Duarte
- Dana Farber Cancer Institute
Boston
- Dana-Farber/brigham and Women's Cancer Center (df/bwcc) at Milford Regional Medical Center
Milford
- Dana-Farber/brigham and Women's Cancer Center (df/bwcc) in Clinical Affiliation With South Shore Hospital
South Weymouth
- Novant Health Oncology Specialists
Winston-Salem
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03858322
Each answer restates registry values shown on this page.
What is NCT03858322?
NCT03858322 is a phase 1 interventional trial sponsored by Dana-Farber Cancer Institute. It studies Carboplatin, Cyclophosphamide and Paclitaxel in Breast Cancer.
Is NCT03858322 recruiting?
As of 18 Nov 2026, it is active and no longer recruiting.
Who leads NCT03858322?
The registry names Rachel Freedman, MD, MPH (principal investigator, Dana-Farber Cancer Institute) as the overall official.
Where does NCT03858322 run?
The registry lists 5 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03858322 study?
The registered drug and biological interventions are Carboplatin, Cyclophosphamide and Paclitaxel.
When is NCT03858322 expected to complete?
The registry lists a primary completion date of 10 Nov 2020 and a study completion date of 30 Dec 2026. The sponsor last updated the record on 13 Aug 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.